Indication prioritization & target validation

Use K Pro to assess whether a target is worth advancing, and to validate that biomarkers behave consistently across data modalities.

• Assess target tractability & druggability: evaluate target tractability, safety profiles, and therapeutic potential using curated databases.

• Validate biomarkers across modalities: test biomarkers and hypotheses across bulk RNA-seq, single-cell, spatial, and clinical data.

What to do: Combine multiple data modalities (RNA-seq, mutation data, etc.) within a cohort to identify candidates that show convergent evidence across layers. Multiomics queries are computationally intensive: start with a specific comparison (two subgroups) rather than "analyze everything."

Example prompt:

In the TCGA-BRCA cohort, integrate RNA-seq gene expression and mutation data. Identify genes that are both differentially expressed and frequently mutated in basal-like versus luminal A patients.

Expected result: A multi-omics integration result showing genes that appear significant across both data modalities.

Follow-up:

Perform an individual gene expression comparison of MSIGDB DNA repair, oxidative stress, and EMT pathway signatures at Bulk RNA level using a violin plot with p-values comparing Basal-like and Luminal TCGA-BRCA patients.